375 related articles for article (PubMed ID: 23241733)
1. Colistin in critically ill patients.
Boisson M; Gregoire N; Couet W; Mimoz O
Minerva Anestesiol; 2013 Feb; 79(2):200-8. PubMed ID: 23241733
[TBL] [Abstract][Full Text] [Related]
2. [Shedding light on the use of colistin: still gaps to be filled].
Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
[TBL] [Abstract][Full Text] [Related]
3. Colistin pharmacokinetics: the fog is lifting.
Couet W; Grégoire N; Marchand S; Mimoz O
Clin Microbiol Infect; 2012 Jan; 18(1):30-9. PubMed ID: 21988234
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of colistin sodium.
Michalopoulos AS; Karatza DC; Gregorakos L
Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):245-55. PubMed ID: 21128824
[TBL] [Abstract][Full Text] [Related]
5. Dosing of colistin-back to basic PK/PD.
Bergen PJ; Li J; Nation RL
Curr Opin Pharmacol; 2011 Oct; 11(5):464-9. PubMed ID: 21835694
[TBL] [Abstract][Full Text] [Related]
6. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients.
Kontopidou F; Plachouras D; Papadomichelakis E; Koukos G; Galani I; Poulakou G; Dimopoulos G; Antoniadou A; Armaganidis A; Giamarellou H
Clin Microbiol Infect; 2011 Nov; 17(11):E9-E11. PubMed ID: 21939468
[TBL] [Abstract][Full Text] [Related]
7. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
8. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
9. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
[TBL] [Abstract][Full Text] [Related]
10. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
[TBL] [Abstract][Full Text] [Related]
11. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
Li J; Nation RL; Turnidge JD; Milne RW; Coulthard K; Rayner CR; Paterson DL
Lancet Infect Dis; 2006 Sep; 6(9):589-601. PubMed ID: 16931410
[TBL] [Abstract][Full Text] [Related]
12. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections.
Huang J; Tang YQ; Sun JY
Scand J Infect Dis; 2010 Apr; 42(4):260-5. PubMed ID: 20085424
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
[TBL] [Abstract][Full Text] [Related]
15. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.
Poulakou G; Bassetti M; Righi E; Dimopoulos G
Future Microbiol; 2014; 9(9):1053-69. PubMed ID: 25340835
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
[TBL] [Abstract][Full Text] [Related]
17. Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients.
Kapoor K; Jajoo M; Dublish S; Dabas V; Gupta S; Manchanda V
Pediatr Crit Care Med; 2013 Jul; 14(6):e268-72. PubMed ID: 23689704
[TBL] [Abstract][Full Text] [Related]
18. Colistin: understanding and applying recent pharmacokinetic advances.
Ortwine JK; Kaye KS; Li J; Pogue JM
Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
